Withings, a Paris, France-based connected health company, raised $60m in Series B funding.
The round was co-led by healthcare investment specialists Gilde Healthcare, and long-term partners and investors, Idinvest Partners and Bpifrance, through their Large Venture funds, as well as BNP Paribas Développement, ODDO BHF Private Equity, and Adelie Capital.
The company intends to use the funds to continue to invest in products and data services that help deliver more personalized, continuous and preventive medicine, to globally scale its dedicated business-to-business division Withings MED PRO and accelerate the development of the next generation of consumer health devices that bring medical grade and predictive capabilities into the home. It also plans to add 100 new positions in the United States and France by the end of the year to strengthen its teams working on research and development, sales, and marketing.
Founded by Cédric Hutchings and Eric Carreel in 2008, and led by Mathieu Letombe, CEO, Withings provides smart products across the health spectrum including activity trackers (Steel, Steel HR, Steel HR Sport, Pulse HR), connected scales (Body Cardio, Body+, Body), blood pressure monitors (BPM Core and BPM Connect), and an advanced sleep system (Sleep). With over 45 technical patents, the company’s portfolio captures more than 20 vital health parameters including blood pressure, ECG, weight, pulse wave velocity, heart rate, activity levels, sleep apnea, and sleep patterns.
Withings’ ongoing healthcare strategy will be guided by its newly appointed global Medical Advisory Board, comprised of eminent medical, research, and scientific leaders: Dr. John Halamka, President of the Mayo Clinic Platform, Dr. Stéphane Laurent, former Head of Clinical Pharmacology in Hôpital Européen Georges Pompidou in Paris, and Craig Lipset, former head of Clinical Innovation at Pfizer.